EyeGate Pharmaceuticals Inc (EYEG)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:EyeGate Pharmaceuticals Inc (EYEG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014019
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical company that offers eye care medicines. The company offers macular edema and non-infectious anterior uveitis. It offers technologies for most prevalent issues in ophthalmic care; the existing lack of patient adherence and patient safety. EyeGate deliver drugs in optimal dosing regimens directly into the ocular tissue in both the anterior and posterior segments of the eye. The company offers EGP-437 that incorporates a reformulated corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues. It also offers drug delivery mechanisms for treating diseases of the eye. EyeGate is headquartered in Waltham, Massachusetts, the US.

EyeGate Pharmaceuticals Inc (EYEG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
EyeGate Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
EyeGate Pharma Raises USD2.6 Million in Venture Financing 13
EyeGate Pharma Raises USD1 Million in Venture Financing 14
Jade Therapeutics To Raise US$0.6 Million In Venture Financing 15
EyeGate Pharma Raises US$1 Million In Venture Financing 16
EyeGate Pharma Secures An Additional US$5.9 Million In Series D Round Of Financing 17
Partnerships 18
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 18
Licensing Agreements 20
EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 20
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 21
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 22
Equity Offering 23
EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 23
EyeGate Pharma Raises USD3.8 Million in Private Placement of Shares and Preferred Stock 24
EyeGate Pharma Raises USD10 Million in Public Offering of Shares 26
EyeGate Pharma Raises USD4.1 Million in IPO 28
Acquisition 30
Eyegate Pharma Acquires Jade Therapeutics 30
EyeGate Pharmaceuticals Inc – Key Competitors 31
EyeGate Pharmaceuticals Inc – Key Employees 32
EyeGate Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 14, 2017: EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 34
Aug 07, 2017: EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 36
May 08, 2017: EyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 37
Feb 23, 2017: EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update 39
Nov 02, 2016: EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update 40
Aug 10, 2016: EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update 41
May 13, 2016: Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update 43
Mar 29, 2016: EyeGate Reports Full-year 2015 Financial Results and Provides Business Update 45
Corporate Communications 46
Nov 01, 2017: EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy 46
Oct 23, 2017: Eye Care Thought Leaders Join EyeGate Scientific Advisory Board 47
Feb 06, 2017: EyeGate Pharmaceuticals Announces Executive Promotions 48
Apr 27, 2016: EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer 49
Government and Public Interest 50
Sep 13, 2016: EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
EyeGate Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
EyeGate Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
EyeGate Pharma Raises USD2.6 Million in Venture Financing 13
EyeGate Pharma Raises USD1 Million in Venture Financing 14
Jade Therapeutics To Raise US$0.6 Million In Venture Financing 15
EyeGate Pharma Raises US$1 Million In Venture Financing 16
EyeGate Pharma Secures An Additional US$5.9 Million In Series D Round Of Financing 17
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 18
EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 20
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 21
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 22
EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 23
EyeGate Pharma Raises USD3.8 Million in Private Placement of Shares and Preferred Stock 24
EyeGate Pharma Raises USD10 Million in Public Offering of Shares 26
EyeGate Pharma Raises USD4.1 Million in IPO 28
Eyegate Pharma Acquires Jade Therapeutics 30
EyeGate Pharmaceuticals Inc, Key Competitors 31
EyeGate Pharmaceuticals Inc, Key Employees 32
EyeGate Pharmaceuticals Inc, Subsidiaries 33

★海外企業調査レポート[EyeGate Pharmaceuticals Inc (EYEG)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SolaCom Technologies, Inc.:企業の戦略・SWOT・財務情報
    SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • UMW Holdings Bhd (UMW):石油・ガス:M&Aディール及び事業提携情報
    Summary UMW Holdings Bhd (UMW) is a diversified company. The company operates through its business divisions such as automotive, equipment, manufacturing and engineering, and oil and gas. Its automotive business manufactures, assembles, markets and distributes passenger cars and commercial vehicles. …
  • Monsanto Company:企業のM&A・事業提携・投資動向
    Monsanto Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Monsanto Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Italiaonline S.p.A. (IOL):企業の財務・戦略的SWOT分析
    Italiaonline S.p.A. (IOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Vivus Inc (VVUS):企業の財務・戦略的SWOT分析
    Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Relentless Resources Ltd (RRL):石油・ガス:M&Aディール及び事業提携情報
    Summary Relentless Resources Ltd (Relentless Resources), formerly New Range Resources Ltd is an oil and gas company that offers oil and gas exploration and development services. The company acquires, explores, operates, manages, produces, and develops crude oil and natural gas in Alberta and Saskatc …
  • MEDITE Cancer Diagnostics Inc (MDIT):医療機器:M&Aディール及び事業提携情報
    Summary MEDITE Cancer Diagnostics Inc (MEDITE), formerly CytoCore, Inc., specializes in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. Its major devices include ultrason …
  • Response Biomedical Corp:企業の戦略的SWOT分析
    Response Biomedical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Medicom Innovation Partner as-医療機器分野:企業M&A・提携分析
    Summary Medicom Innovation Partner a/s (Medicom), formerly Bang & Olufsen Medicom, a subsidiary of Phillips-Medisize Corp, is a medical device company that develops electronic-based drug delivery and connected health systems. The company offers services such as device strategy and direction, device …
  • HD Supply, Inc. (HDS):企業の財務・戦略的SWOT分析
    HD Supply, Inc. (HDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lipigon Pharmaceuticals AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Lipigon Pharmaceuticals AB (Lipigon Pharmaceuticals) is a lipid biology company that discovers and develops novel therapies for lipid disorders and other cardiometabolic risk factors. The company offers developing its products in various therapeutic areas such as cardiovascular and metabolic …
  • Albéa Beauty Holdings S.A.:戦略・SWOT・企業財務分析
    Albéa Beauty Holdings S.A. - Strategy, SWOT and Corporate Finance Report Summary Albéa Beauty Holdings S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Synlogic Inc (SYBX):製薬・医療:M&Aディール及び事業提携情報
    Summary Synlogic Inc (Synlogic), formerly TMC Therapeutics Inc is a clinical stage drug development company that develops novel class of living medicines for the treatment of rare and genetic metabolic diseases, by applying synthetic biology to probiotics. The company’s pipeline includes SYNB1020 a …
  • DEA Deutsche Erdoel AG:石油・ガス:M&Aディール及び事業提携情報
    Summary DEA Deutsche Erdoel AG (DEA), a subsidiary of Letterone Holdings S.A., is an upstream company that explores for and produces oil and natural gas. The company operates onshore and offshore projects in Egyptian Nile delta, Mittelplate Island and Norwegian coast line and other regions. It also …
  • Shanghai Jin Jiang International Hotels (Group) Co Ltd:企業の戦略・SWOT・財務情報
    Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Naspers Limited:企業のM&A・事業提携・投資動向
    Naspers Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Naspers Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Ferrellgas Partners, L.P.:企業の戦略・SWOT・財務分析
    Ferrellgas Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Ferrellgas Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Xellia Pharmaceuticals ApS-製薬・医療分野:企業M&A・提携分析
    Summary Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products …
  • Rottneros AB (RROS):企業の財務・戦略的SWOT分析
    Rottneros AB (RROS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Oi S.A.:企業の戦略・SWOT・財務情報
    Oi S.A. - Strategy, SWOT and Corporate Finance Report Summary Oi S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆